Engineered CXCL12 alpha locked dimer polypeptide

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8524670
APP PUB NO 20110091410A1
SERIAL NO

12956514

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides a novel CXCL12-α2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATIONMILWAUKEE WI

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Peterson, Francis C Racine, US 92 3682
Sakmar, Thomas New York, US 4 10
Seibert, Christoph H Frankfurt am Main, DE 4 10
Veldkamp, Christopher T Milwaukee, US 4 10
Volkman, Brian F Muskego, US 9 10

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 3, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00